E3 Ligase Ligand-Linker Conjugate

Thalidomide-4-O-C2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a designated linker for use in PROTAC technology. This compound is designed to facilitate targeted protein degradation by harnessing the cellular ubiquitin-proteasome system. Its applications extend to studies in drug discovery and cellular signaling, enabling researchers to investigate the modulation of protein levels with precision.

Thalidomide-azetidine-C-PIP-C-boc is an E3 ligase ligand-linker conjugate that incorporates Thalidomide, serving as a recruiter for the cereblon (CRBN) protein. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by acting as a critical intermediate for the synthesis of complete PROTAC molecules. Its utility in research includes applications in targeted protein degradation strategies, providing a platform for innovative therapeutic development.

Thalidomide-O-C3-NH2 is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from Thalidomide with a specialized linker for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation by recruiting specific substrates to the ubiquitin-proteasome system. Thalidomide-O-C3-NH2 is instrumental for research applications in protein regulation and therapeutic development, particularly in understanding cellular processes and disease mechanisms.

Thalidomide-O-PEG2-propargyl is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a key component of the E3 ubiquitin ligase complex. This compound incorporates a two-unit PEG linker and a propargyl group, making it suitable for click chemistry applications. Thalidomide-O-PEG2-propargyl can facilitate copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling the conjugation of various azide-containing molecules, and is particularly useful in the development of targeted protein degradation strategies in chemical biology research.

Thalidomide-Piperazine-PEG1-COOH serves as an E3 ligase ligand-linker conjugate, integrating a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. It is suitable for research applications aimed at investigating protein regulation and therapeutic strategies in cancer and other diseases.

Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand covalently attached to a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology by engaging the E3 ubiquitin ligase cereblon. Its primary applications include research in protein homeostasis, cancer therapeutics, and the development of new drug modalities in the field of targeted protein degradation.

Thalidomide-piperazine-Boc is an E3 ligase ligand-linker conjugate that serves as an intermediate in the synthesis of PROTAC targeting B-cell lymphoma 6 protein (BCL6). This compound plays a significant role in targeted protein degradation, facilitating the selective destruction of BCL6 and aiding in research related to cancer therapeutics. Its application is essential for studies focusing on E3 ligase modulation and PROTAC development in oncology.

Thalidomide-Propargyne-PEG2-COOH is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG-based linker suitable for PROTAC applications. This compound features an alkyne moiety, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). It serves as a valuable tool for research in targeted protein degradation and the development of innovative therapeutic strategies.

Thalidomide-NH-PEG2-COOH is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from thalidomide, combined with a PEG-based linker. This compound is designed to enhance targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology. It serves as a valuable tool for research in cellular biology and therapeutic applications by enabling precise modulation of protein levels in various biological contexts.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation in cellular systems. Its unique structure allows for selective engagement of E3 ligases, providing valuable applications in therapeutic research and drug discovery focused on the modulation of protein levels.

Thalidomide-O-C2-acid is an E3 ligase ligand-linker conjugate that features the Thalidomide-derived cereblon ligand, combined with a suitable linker for applications in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted protein degradation, enabling researchers to manipulate protein levels within cells. Its design supports the development of innovative therapeutic strategies by leveraging the ubiquitin-proteasome system for potential applications in cancer and other diseases.

Thalidomide-5-O-CH2-COOH is an E3 ligase ligand-linker conjugate that functions as a selective ligand for the Cereblon (CRBN) protein. Its primary role is to facilitate the recruitment of CRBN, making it a valuable intermediate in the synthesis of PROTAC (Proteolysis Targeting Chimeras) molecules targeting CRBN. This compound is essential for research related to targeted protein degradation and therapeutics aimed at modulating cellular proteins through ubiquitin-proteasome pathways.

Thalidomide-4-O-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from Thalidomide. This compound is designed for use in PROTAC (proteolysis targeting chimeras) technology, facilitating the targeted degradation of specific proteins within cellular systems. Its utility in research includes studying protein turnover and exploring therapeutic strategies for various diseases through targeted protein modulation.

Thalidomide-4-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate utilizing the cereblon ligand derived from thalidomide. This compound plays a critical role in the assembly of PROTAC (proteolysis targeting chimera) technologies, facilitating targeted protein degradation. It is primarily used in pharmacological research to investigate E3 ligase-mediated protein modulation and to develop innovative therapeutic strategies in disease treatment.

Thalidomide-O-amido-C4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates a cereblon ligand derived from Thalidomide. This compound is primarily utilized in the development of PROTACs (proteolysis targeting chimeras), enabling targeted protein degradation. Its unique structure facilitates the recruitment of cognate E3 ligases, thereby promoting the efficient ubiquitination and subsequent degradation of specific target proteins, making it a valuable tool in chemical biology and therapeutic research.

Thalidomide-PEG4-COOH is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG4 linker. This compound facilitates the targeted protein degradation through the PROTAC (Proteolysis Targeting Chimera) technology, enhancing the selective modulation of protein levels in cellular environments. It serves as a valuable tool for researchers exploring protein homeostasis, pharmacological modulation, and therapy development in various disease contexts.